Navigation Links
Combination therapy may enhance gemcitabine activity

PHILADELPHIA Oncologists who treat patients with pancreatic cancer may be one step closer to understanding why gemcitabine, the only currently available treatment, works in some cases but not in others, according to a paper in Cancer Discovery, a journal of the American Association for Cancer Research.

David Tuveson, M.D., Ph.D., a professor of pancreatic cancer medicine at the University of Cambridge, utilized a laboratory model to test the combination of gemcitabine and nab-paclitaxel in pancreatic cancer.

"The combination has shown promise in an early clinical trial, and clinical results from a pivotal phase III trial will be reported in 2013," said Tuveson. "However, we know very little about the mechanism of action because tumor samples have been so small."

Using a laboratory model of metastatic pancreatic ductal adenocarcinoma, the researchers showed that combination treatment increased intratumoral gemcitabine levels due to a marked decrease in the primary gemcitabine metabolizing enzyme, cytidine deaminase.

Paclitaxel appeared to reduce these levels through reactive oxygen species-mediated degradation, resulting in increased stabilization of gemcitabine. Tuveson said understanding these mechanisms of action are important and will lead to better administration of the therapeutic combination if the larger human trials prove positive.

"For example, we predict from this mechanistic study that nab-paclitaxel may be most effective if we administer it first, and delay administration of the gemcitabine. The next step is to test this prediction, since it could help a great deal with patient treatment," said Tuveson.


Contact: Jeremy Moore
American Association for Cancer Research

Page: 1

Related medicine news :

1. Combination drug therapy urged to battle lung cancer
2. Healthy Children, Safe Homes a Winning Combination
3. Ganetespib showed activity in KRAS-mutant NSCLC as monotherapy and in combinations
4. Combination therapy shows positive response for children with ADHD
5. Severe alcoholic hepatitis: An effective combination of 2 treatments
6. Combination epigenetic therapy clinical trial results
7. NYUCN receives $2.8 million NIH/NIAID grant to study combination HIV prevention for Kenyan youth
8. Combination of available tests helps predict Alzheimers disease risk
9. Combination therapies for drug-resistant cancers
10. Combination therapy beneficial for head and neck skin carcinomas, UNC study shows
11. Phase II study shows new cancer drug combination significantly delays breast cancer progression
Post Your Comments:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing an ... to overcome a rare and deadly chromosome abnormality. , After struggling since birth ...
(Date:10/13/2017)... ... 13, 2017 , ... While it’s often important to take certain medications during ... Austin, Texas, has identified a solution. , She developed a prototype for MOTION LIGHT-UP ... such, it eliminates the need to turn on a light when taking medication during ...
(Date:10/13/2017)... , ... October 13, 2017 , ... PurhealthRX , ... Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize ... providing a CBD form that can be easily incorporated into liquid products, while reducing ...
(Date:10/13/2017)... ... 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes in ... the facility as part of a disaster drill on October 3rd. , Apple Rehab ... City Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid ...
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
(Date:10/2/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: ... Consulting, LLC , and named its founder as Diplomat,s ... Tennessee , will operate under Diplomat ... service offerings for health care partners to include IT ... "In an interoperable world, technology delivers comprehensive ...
Breaking Medicine Technology: